Citation Impact
Citing Papers
Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.
1992
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
2018 Standout
Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period
2006
A Model for Perioperative Outpatient Management of Anticoagulation in High-Risk Patients: An Evaluation of Effectiveness and Safety
2001
Incidence of Venous Thromboembolism in Patients Hospitalized with Cancer
2006
Oral antiplatelet therapy for acute ischaemic stroke
2014
Cost‐Effectiveness of Enoxaparin versus Low‐Dose Heparin for Prophylaxis Against Venous Thrombosis after Major Trauma
1998
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
1996
Epidural analgesia for pain relief following hip or knee replacement
2003
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.
1998
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
1994
European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke
2016
A Population-Based Study of the Effectiveness of Inferior Vena Cava Filter Use Among Patients With Venous Thromboembolism
2000
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism
2012
The validation and reproducibility of the pulmonary embolism severity index
2010
A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty*
2000
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Thromboembolic Disease Prophylaxis in Patients With Hip Fracture
2005
Pulmonary Embolism
1998
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
2001
Major bleeding after hospitalization for deep-venous thrombosis
1999
Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty
1998
PRACTICAL MANAGEMENT OF VENOUS THROMBOEMBOLISM FOLLOWING PELVIC FRACTURES
1997
Venographic comparison of subcutaneous low–molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis
1999
Predictors of Rehospitalization for Symptomatic Venous Thromboembolism after Total Hip Arthroplasty
2000
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease
2001
Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement
1999
Proficient and Cost-Effective Approaches for the Prevention and Treatment of Venous Thrombosis and Thromboembolism
2000
Prognostic Models for Selecting Patients With Acute Pulmonary Embolism for Initial Outpatient Therapy
2007
Mechanisms of Thrombus Formation
2008 Standout
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
2001
A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
1998
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Ambulatory management of pulmonary embolism: a pragmatic evaluation
2010
A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous Thromboembolism
2000
Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants
2003
Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis
2012
Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin
2000
Antithrombotic Therapy Practices in US Hospitals in an Era of Practice Guidelines
2005
Comparison of the Efficacy and Safety of Low Molecular Weight Heparins and Unfractionated Heparin in the Initial Treatment of Deep Venous Thrombosis
1996
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
2004 StandoutNature
Medical complications after stroke
1999
Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism
2000
Predictors of Recurrence After Deep Vein Thrombosis and Pulmonary Embolism
2000 Standout
Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy
2001
New Antithrombotic Drugs
2012
Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor
2010
Antithrombotic Therapy for VTE Disease
2016 Standout
Platelet-Active Drugs
1998
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study
2002
Prevention of venous thromboembolism after acute ischemic stroke
2005
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis
2001
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Expanding Eligibility for Outpatient Treatment of Deep Venous Thrombosis and Pulmonary Embolism With Low-Molecular-Weight Heparin
1998
Unresolved issues in anticoagulant therapy
2003
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Deep-vein thrombosis
1999
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients
2000
Can Selected Patients With Newly Diagnosed Pulmonary Embolism Be Safely Treated Without Hospitalization? A Systematic Review
2012
Treatment of Deep-Vein Thrombosis
2004
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome
1995 Standout
A Clinical Prediction Rule for Identifying Short-Term Risk of Adverse Events in Patients With Pulmonary Thromboembolism
2007
Once-Daily Enoxaparin in The Outpatient Setting Versus Unfractionated Heparin in Hospital for the Treatment of Symptomatic Deep-Vein Thrombosis
2005
Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery
2000
Perioperative Management of Patients Receiving Oral Anticoagulants
2003
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
2001
Thromboprophylaxis with 60 mg Enoxaparin Is Safe in Hip Trauma Surgery
2001
Out of hospital treatment of acute pulmonary embolism in patients with a low NT‐proBNP level
2010
Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group
1997
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
2008
A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism
2005
Home treatment in pulmonary embolism
2009
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Recurrent Venous Thrombosis and Heparin Therapy
1999
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Deep Venous Thrombosis
2004
Platelet Activation and Atherothrombosis
2007 Standout
Managing Oral Anticoagulant Therapy
2001
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
2007
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials
2011
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism
1997
Deep vein thrombosis and air travel: record linkage study
2003
Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery
1998
CHARGE syndrome: an update
2007
Effectiveness and Economic Impact Associated With a Program for Outpatient Management of Acute Deep Vein Thrombosis in a Group Model Health Maintenance Organization
2000
Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism
2006
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians
2011
Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?
2002
Medical management of patients with brain tumors
2006
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients
2000
Malignant Gliomas in Adults
2008 Standout
Use of Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolic Disease: Answers to Frequently Asked Questions
1998
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
2003
Consensus Guidelines for Coordinated Outpatient Oral Anticoagulation Therapy Management
1997
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
2008 Standout
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis
2005
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Economic Evaluation of Outpatient Treatment With Low-Molecular-Weight Heparin for Proximal Vein Thrombosis
1999
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
2005
Incidence and Time Course of Thromboembolic Outcomes Following Total Hip or Knee Arthroplasty
1998
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
2005
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Venous thromboembolism and fractured neck of femur
2005
Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting
2004
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
2011
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial
2011
Prevention of Venous Thromboembolism
2008 Standout
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
2004
Mechanical thrombectomy in patients with deep venous thrombosis
2001
Venous Thromboembolism Associated With Hip and Knee Arthroplasty: Current Prophylactic Practices and Outcomes
1992
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
2006
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study
2011
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer
2006
Heparin
1991
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Outpatient treatment of symptomatic pulmonary embolism: A systematic review and meta-analysis
2013
Thrombosis in the Emergency Department
1999
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
An Epidemiologic Study of Risk Factors for Deep Vein Thrombosis in Medical Outpatients
2000
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Economic Evaluation of the MEDENOX Trial: A Canadian Perspective
2002
Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery
2003
High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial
2013
Deep vein thrombosis
2005
Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement
1999
The worcester venous thromboembolism study
2006
A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma
1996
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Risk of Fatal Pulmonary Embolism in Patients With Treated Venous Thromboembolism
1998
The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin<subtitle>A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty</subtitle>
1998
A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty
2003
Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review
2009
Management of Acute Proximal Deep Vein Thrombosis
2002
Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty
1997
Efficacy of Unfractionated Heparin, Low Molecular Weight Heparin and Both Combined for Releasing Total and Free Tissue Factor Pathway Inhibitor
1998
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage
2015
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Prevention of Venous Thromboembolism
1998
Hemorrhagic Complications of Anticoagulant Treatment
2004
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Management of Venous Thromboembolism
1996
Venous Thromboembolism in Spinal Cord Injury Patients
1992
Low Accuracy of Color Doppler Ultrasound in the Detection of Proximal Leg Vein Thrombosis in Asymptomatic High-Risk Patients
1992
Antithrombotic Therapy for Venous Thromboembolic Disease
2004 Standout
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence
2005
Early versus Delayed Introduction of Oral Vitamin K Antagonists in Combination with Low-Molecular-Weight Heparin in the Treatment of Deep Vein Thrombosis
1998
Platelet-Active Drugs
2001
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis
2004
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
2004
Extended Venous Thromboembolism Prophylaxis After Total Hip Replacement<subtitle>A Comparison of Low-Molecular-Weight Heparin With Oral Anticoagulant</subtitle>
2002
Management of Anticoagulation before and after Elective Surgery
1997
Aspirin in the prevention and treatment of venous thromboembolism
2006
Outpatient treatment of deep vein thrombosis: translating clinical trials into practice
1999
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Clinical Outcome and Cost of Hospital vs Home Treatment of Proximal Deep Vein Thrombosis With a Low-Molecular-Weight Heparin
2000
CHD7 cooperates with PBAF to control multipotent neural crest formation
2010 StandoutNature
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
1992
Deep venous thrombosis: a new task for primary health care A randomised economic study of outpatient and inpatient treatment
2004
Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy
2000
Venous Thromboembolism
1999
Low molecular weight heparin in prevention of perioperative thrombosis.
1992
Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis.
2002
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty
2001
Escala de riesgo de eventos adversos a corto plazo en pacientes con tromboembolia pulmonar
2007
Impact of the patient population on the risk for heparin-induced thrombocytopenia
2000 Standout
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
1998
DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells
2003 StandoutNobel
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
1997
Leg compression and ambulation is better than bed rest for the treatment of acute deep venous thrombosis.
2003
Venous thromboembolism in trauma patients: A review
2001
Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread
1999
Acute Deep Vein Thrombosis: Early Mobilization Does not Increase the Frequency of Pulmonary Embolism
2001
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
THROMBOPROPHYLAXIS AND DEATH AFTER TOTAL HIP REPLACEMENT
1996
Acquisition of Host-Derived CD40L by HIV-1In Vivoand Its Functional Consequences in the B-Cell Compartment
2010
Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism
2003
Vena caval filters: a comprehensive review
2000
Management of Iliofemoral Thrombosis in a Pregnant Patient With Heparin Resistance
1997
Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery.
1996
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
2002
Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis
2003
Treating Patients With ‘Wake-Up’ Stroke
2008
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis
1999
Outpatient Use of Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity
1999
Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells
2002
Bed Rest in Deep Vein Thrombosis and the Incidence of Scintigraphic Pulmonary Embolism
1999
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Comparison of a once Daily with a twice Daily Subcutaneous Low Molecular Weight Heparin Regimen in the Treatment of Deep Vein Thrombosis
1998
Starting prophylaxis for venous thromboembolism postoperatively.
1995
Prevention of Deep Vein Thrombosis after Major Knee Surgery - A Randomized, Double-Blind Trial Comparing a Low Molecular Weight Heparin Fragment (Enoxaparin) to Placebo
1992
Safety of Tirofiban in Acute Ischemic Stroke
2011
Duration of anticoagulation following venous thromboembolism: a meta-analysis.
2005
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Perioperative low-molecular-weight heparin. Is it effective and safe
1995
Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
1999
Venous Thromboembolism and Cancer: Risks and Outcomes
2003
Natural History of Venous Thromboembolism
2003
Home versus in-patient treatment for deep vein thrombosis
2007
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Dalteparin as Periprocedure Anticoagulation for Patients on Warfarin and at High Risk of Thrombosis
2001
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
‘Silent’ Cerebral Infarction Is Associated With Hypercoagulability, Endothelial Cell Damage, and High Lp(a) Levels in Elderly Japanese
1996
Prophylaxis of postoperative thromboembolism with low molecular weight heparins
1993
Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.
1994
Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis
2000
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
2006
Duplex Ultrasonography for the Detection of Deep Vein Thrombi After Total Hip or Knee Arthroplasty
1993
VENOUS THROMBOSIS PROPHYLAXIS FOR UROLOGICAL LAPAROSCOPY: FRACTIONATED HEPARIN VERSUS SEQUENTIAL COMPRESSION DEVICES
2005
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke
2014
Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis
1999
Relation Between the Time to Achieve the Lower Limit of the APTT Therapeutic Range and Recurrent Venous Thromboembolism During Heparin Treatment for Deep Vein Thrombosis
1997
Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement
1998
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
1997
The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden
1997
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
2002 StandoutScience
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.
2001
Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism
2004
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.
2003
A Meta-analysis of Methods to Prevent Venous Thromboembolism Following Total Hip Replacement
1994
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis
2000
Warfarin therapy: evolving strategies in anticoagulation.
1999
Low-Molecular-Weight Heparin Versus Saphenofemoral Disconnection for the Treatment of Above-Knee Greater Saphenous Thrombophlebitis: A Prospective Study
2003
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
1991
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism
2003
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis
1999
Guidelines for the Early Management of Patients With Ischemic Stroke
2003
Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
1994
Low-molecular-weight heparin in the management of Tyrousseau's syndrome
1997
Low-Molecular-Weight Heparins
1997 Standout
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Replacing Inpatient Care by Outpatient Care in the Treatment of Deep Venous Thrombosis – An Economic Evaluation
1998
Comparison of Low-Molecular-Weight Heparin, Administered Primarily at Home, with Unfractionated Heparin, Administered in Hospital, and Subcutaneous Heparin, Administered at Home for Deep-Vein Thrombosis
1999
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta-analyses
1997
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
2006
Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients
1995
Prevention of deep-vein thrombosis after total hip and knee replacement
2004
Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery
1996
Home versus in-patient treatment for deep vein thrombosis
2018
Prevention of Venous Thromboembolism
1995
Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.
1994
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
2004
Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival
2006
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
2002
Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism
2014
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
2014
Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped
2002
Comparison of Warfarin and External Pneumatic Compression in Prevention of Venous Thrombosis After Total Hip Replacement
1992
Prevention and Treatment of Thrombo-embolic Disease in Gynaecological Surgery
1999
Outpatient Treatment of Pulmonary Embolism with Dalteparin
2000
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
2017
Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism
2010
Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis
2001
Cost-effectiveness of Enoxaparin vs Low-Dose Warfarin in the Prevention of Deep-Vein Thrombosis After Total Hip Replacement Surgery
1995
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
1993
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
2013
Works of Jacques Leclerc being referenced
A Low-Molecular-Weight Heparinoid Compared with Unfractionated Heparin in the Prevention of Deep Vein Thrombosis in Patients with Acute Ischemic Stroke
1992
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
1996
Age-associated risks of prophylactic anticoagulation in the setting of hip fracture
1994
Choanal atresia and associated anomalies
1987
The low molecular weight heparin Enoxaparin inhibits the consumption of factor VII and prothrombin activation in vivo associated with elective knee replacement surgery
1992
Hemostatic markers in acute transient ischemic attacks.
1994
Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis
1995
Low-Molecular-Weight Heparinoid Orgaran Is More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture
1996
Presence of Host ICAM-1 in Laboratory and Clinical Strains of Human Immunodeficiency Virus Type 1 Increases Virus Infectivity and CD4+-T-Cell Depletion in Human Lymphoid Tissue, a Major Site of Replication In Vivo
2002
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial
2007